[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Various Countries Allergic Rhinitis Markets Examined in Topical GlobalData Reports Now Available at MarketPublishers.com

07 Oct 2016 • by Natalie Aster

LONDON – MarketPublishers.com is excited to inform that topical GlobalData reports on the various countries AR markets are now available at its online catalogue.

Allergic Rhinitis - 5EU Drug Forecast and Market Analysis to 2024. As of 2014, the value of the sales allergic rhinitis (AR) products across the 5EU reached a total of USD 2.53 billion. The AR market in the region is projected to continue to see stagnation, with no key events taking place over the next decade. There are no pipeline AR products projected to be launched in the reviewed countries in the coming years. The patent expirations of the top-selling Nasacort and Nasonex will likely have the most adverse impact on the 5EU AR market. The report gives an overview of the market, covering epidemiology, diagnosis, symptoms, therapeutic regimens, etc. alongside an investigation on the competitive scenario. It gives details about the key drugs in the countries discussed, including descriptions of the products, efficacy and safety profiles and also a SWOT analysis. Sales forecasts for the top drugs to 2024 are included as well…

Allergic Rhinitis - Japan Drug Forecast and Market Analysis to 2024. The Japanese allergic rhinitis market has declined at a sluggish pace over the past 10 years due to its saturation with relatively efficacious and safe standard therapies, like antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists, and has also seen soaring generic competition.  In spite of the surging prevalence of the disease, and a large percentage of patient population not satisfied with the available treatment modes, the market size for symptomatic therapies alone will likely shrink, as the remaining branded drugs are losing patent protection. There is a rising shift in prescription AR products gaining OTC status, thus driving patients to pharmacy institutions rather than to physicians, further weakening the prescription AR market. The huge, crowded generic AR market has been mainly unappealing to drug makers. Hence, only two symptomatic treatments are set to launch until 2024…

Allergic Rhinitis - US Drug Forecast and Market Analysis to 2024. In the USA, the AR product sales value amounted to USD 2.8 billion as of 2014. As in the worldwide markets, this decline is expected to be stimulated largely by the patent expirations of a slew of INCS, and the launch of the first OTC INCS in the local pharmacies. Notwithstanding the fact that the prevalence rate of AR patients will likely increase in the offing, only one drug product is anticipated to be introduced during this period, which is forecast to face tough competition upon entry and grab modest market share. The report gives a detailed market analysis, identifying products that will likely ensure a robust return; evaluates the changing competitive landscape for AR; identifies the drugs holding the most promising sales potential; gives an insightful and comprehensive analysis of the performance of drugs; as well as offers sales forecasts for drug products through to 2024 in the country…

More topical studies by this publisher are available at GlobalData page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest